MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis

Gelijkaardige items

• A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
  door: Hellings, Peter, et al.
  Gepubliceerd in: (2015)
• A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
  door: Price, David, et al.
  Gepubliceerd in: (2013)
• A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
  door: Scadding, Glenis, et al.
  Gepubliceerd in: (2013)
• Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
  door: Price, David, et al.
  Gepubliceerd in: (2013)
• A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
  door: Hellings, Peter, et al.
  Gepubliceerd in: (2013)